@article{add2a83268174245b4aab89351ede643,
title = "Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update",
keywords = "DERUXTECAN T-DXD, TRASTUZUMAB-DERUXTECAN, OPEN-LABEL, PHASE-III, CLINICAL-PRACTICE, CAPECITABINE, PROGRESSION, LAPATINIB, CHEMOTHERAPY, COMBINATION",
author = "Gabriel Rinnerthaler and C Singer and E Petru and D Egle and A Petzer and U Pluschnig and Gampenrieder, {Simon Peter} and G Pfeiler and M Gnant and B Grunberger and P Krippl and K Strasser-Weippl and C Suppan and C Brunner and R Pusch and M Sandholzer and M Balic and R Bartsch",
note = "Rinnerthaler, Gampenrieder: Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical UniversitySalzburg, M{\"u}llner Hauptstr. 48, 5020 Salzburg, Austria. ",
year = "2022",
doi = "10.1007/s00508-022-02082-3",
language = "English",
journal = "WIENER KLINISCHE WOCHENSCHRIFT",
issn = "0043-5325",
publisher = "Springer Nature",
}